Amgen, an American multinational biopharmaceutical company, completed a $100m investment in Neumora Therapeutics, a clinical-stage biopharmaceutical company. “This partnership with Amgen underscores the vast potential of precision drug development for brain diseases; insights generated by deCODE will further enhance Neuroma’s data-driven precision medicine approach. We are also excited to expand our pipeline with potential best-in-class programs targeting casein kinase 1 delta and glucocerebrosidase for neurodegenerative diseases. Neumora is poised to become a pioneer in precision drug development for brain diseases and we look forward to working with Amgen to advance promising new medicines for patients in need of better treatment options,” Paul L. Berns, Neumora Co-Founder, Chairman and CEO.